GC Biopharma said it has won a record bid to supply a total of 5.94 million doses of its influenza vaccine, GCFLU, to Thailand in 2025. The supply includes both public and private market segments, in partnership with the Government Pharmaceutical Organization (GPO) and the Department of Disease Control (DDC) under Thailand’s Ministry of Public Health.

Thailand is among the few countries required to apply both northern and southern hemisphere vaccination guidelines due to its geographic location, leading to year-round demand for flu vaccines.

GC Biopharma successfully secured bids for both hemispheric supply contracts led by GPO, as well as a national procurement order from DDC, marking a milestone in the company’s export history.

Since entering the Thai flu vaccine market in 2014, GC Biopharma has steadily increased its export volume each year. With the latest contract, the company’s cumulative vaccine supply to Thailand is expected to surpass 15 million doses. The volume of doses supplied to the Thai private sector also surged by 112 percent compared to the previous year.

GCFLU is now exported to 63 countries worldwide, with both the number of markets and annual shipment volumes steadily rising.

The vaccine has established a strong presence in the global influenza vaccine market, bolstered by its selection as the largest flu vaccine supplier to international organizations under the World Health Organization (WHO). GC Biopharma has cumulatively produced over 300 million doses of flu vaccine to date.

“We have seen strong momentum in overseas contracts, thanks to regulatory support from the Ministry of Food and Drug Safety, including streamlined export certification and accelerated lot release procedures,” GC Biopharma Global Business Division Head Lee Woo-jin said. “With a long track record of product reliability recognized by global health organizations, we will continue to promote the excellence of GCFLU worldwide.”